Healio Rheumatology Current Issue
The following articles appeared in the print edition of Healio Rheumatology.
Table of Contents
- Shelter from the cytokine storm: The changing role for rheumatology in COVID-19 Rob Volansky
-
- How did rheumatology wind up in the cytokine storm? Leonard H. Calabrese, DO
- EULAR: Rheumatologist, oncologist collaboration 'pivotal' to enhance checkpoint inhibitor management Jason Laday
- Annual price hikes for RA biologics greatly 'eroded' Medicare Part D cost savings Jason Laday
- Biologic DMARD use linked to lower cardiovascular risk in RA Jason Laday
- Cytokine storm in COVID-19 may drive T-cell depletion, exhaustion Jason Laday
- Evidence still lacking for prophylactic chloroquine, hydroxychloroquine in COVID-19 Jason Laday
- Five steps U.S. federal, state regulators can take to ensure drug access during COVID-19 pandemic Jason Laday
- Patients who fail to meet 2019 EULAR/ACR lupus criteria amass less damage Jason Laday
-
- Serious infection responsible for 1 in 10 gout hospitalizations Jason Laday
- CDC offers guidance to patients with chronic disease 'living with uncertainty' during COVID-19 Rob Volansky
- A 'triumph of hope over facts': The rise and fall of hydroxychloroquine for COVID-19 Rob Volansky
- Breathing 'Rheum' in COVID-19 Hotspots: Detroit juggles poverty, protests, and possible resurgence Rob Volansky
- Gout linked to greater risk for heart failure among older adults Jason Laday
- NYC case series indicates biologics, JAK inhibitors did not worsen COVID-19 outcomes Jason Laday
- Physiotherapy counseling plus FitBit promote physical activity in RA, lupus Jason Laday